Precigen, Inc.
NASDAQ:PGEN
1.13 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Precigen, Inc. |
Symbool | PGEN |
Munteenheid | USD |
Prijs | 1.13 |
Beurswaarde | 330,941,970 |
Dividendpercentage | 0% |
52-weken bereik | 0.65 - 1.93 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Helen Sabzevari MPH, Ph.D. |
Website | https://www.precigen.com |
An error occurred while fetching data.
Over Precigen, Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)